Literature DB >> 17251996

Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.

Sheldon Chen1, Nishant Jalandhara, Daniel Batlle.   

Abstract

Vasopressin-2 receptor antagonists, collectively known as the 'vaptans', provide a new approach to the treatment of hyponatremia; therefore, an updated Review of the pathophysiology of hyponatremia is particularly timely. After briefly defining hyponatremia and introducing its clinical aspects and complications, we present an approach to the diagnosis and evaluation of hyponatremia that is based primarily on the often-underused concept of free water clearance and, more specifically, the electrolyte-free water clearance. Then we review the use of vasopressin receptor antagonists in the management of hyponatremia from the standpoint of their pharmacology, their mechanism of action, and available efficacy data from clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251996     DOI: 10.1038/ncpneph0401

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  5 in total

Review 1.  Pharmacology of vasopressin antagonists.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2008-09-03       Impact factor: 4.214

2.  Tolvaptan.

Authors:  Jalal K Ghali; Bashar Hamad; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

3.  Vasopressin receptor antagonists and their role in clinical medicine.

Authors:  Girish Narayen; Surya Narayan Mandal
Journal:  Indian J Endocrinol Metab       Date:  2012-03

4.  Treatment of euvolemic hyponatremia in the intensive care unit by urea.

Authors:  Guy Decaux; Caroline Andres; Fabrice Gankam Kengne; Alain Soupart
Journal:  Crit Care       Date:  2010-10-14       Impact factor: 9.097

5.  The role of v2 receptor antagonists in the treatment of hyponatremia.

Authors:  Biff F Palmer
Journal:  Electrolyte Blood Press       Date:  2013-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.